SubHero Banner

Tagrisso® (osimertinib) – New Indication

April 18, 2017 - The FDA approved Astra Zeneca’s Tagrisso® (osimertinib), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Download PDF